Pre‐and post‐HSCT use of TKI therapy for fusion‐driven B‐ALL : A case series of five pediatric, adolescent and young adult patients
Cancer Reports · 2023
DOI: 10.1002/cnr2.1901 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Reports, 2023. Verfasst von Savannah S Shumock und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, ALSF.
Abstract (Originalsprache)
Background
The development of tyrosine kinase inhibitors (TKIs) has significantly improved survival rates among patients with Philadelphia chromosome (Ph+) B cell acute lymphoblastic leukemia (B‐ALL). Ph‐like B‐ALL patients lack the BCR::ABL1 translocation but share gene expression profiles with Ph+ B‐ALL. The role of TKIs for Ph‐like patients pre‐ and post‐hematopoietic stem cell transplantation (HSCT) is not yet clear. Case Here we present five cases of pediatric, adolescent, and young adult patients who presented with Ph‐like B‐ALL or CML in B‐ALL blast phase who were treated with personalized TKI regimens pre‐ and post‐HSCT.
Conclusion
This report describes several novel Ph‐like fusions as well as combinations of TKIs with chemotherapy or immunotherapy not yet reported in the pediatric population. This case series provides real‐world experience highlighting the potential application of pre‐ and post‐HSCT use of TKIs in a subset of patients with targetable fusions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, University of California, San Francisco, California, USA.
- Department of Pediatrics, Benioff Children's Hospitals, University of California, San Francisco, California, USA.
ORCID-Profile: Savannah S Shumock, William C Temple, Amanda Marinoff, E Alejandro Sweet-Cordero, Michelle Hermiston, Christine Higham, Elliot Stieglitz
Förderung
- NCI NIH HHS
- NIH HHS
- ALSF
- National Institutes of Health
Zitieren
APA
Shumock, S. S., Temple, W. C., Marinoff, A., Aaronson, K., Southworth, E., Xirenayi, S., Lee, A. G., Leung, S. G., Sweet-Cordero, E. A., Hermiston, M., Higham, C., & Stieglitz, E. (2023). Pre‐and post‐HSCT use of TKI therapy for fusion‐driven B‐ALL : A case series of five pediatric, adolescent and young adult patients. Cancer Reports. https://doi.org/10.1002/cnr2.1901
Vancouver
Shumock SS, Temple WC, Marinoff A, Aaronson K, Southworth E, Xirenayi S, et al. Pre‐and post‐HSCT use of TKI therapy for fusion‐driven B‐ALL : A case series of five pediatric, adolescent and young adult patients. Cancer Reports. 2023. doi:10.1002/cnr2.1901
BibTeX
@article{Shumock2023,
author = {Shumock, Savannah S and Temple, William C and Marinoff, Amanda and Aaronson, Kathryn and Southworth, Erica and Xirenayi, Simayijiang and Lee, Alex G and Leung, Stanley G and Sweet-Cordero, E Alejandro and Hermiston, Michelle and Higham, Christine and Stieglitz, Elliot},
title = {Pre‐and post‐HSCT use of TKI therapy for fusion‐driven B‐ALL : A case series of five pediatric, adolescent and young adult patients},
journal = {Cancer Reports},
year = {2023},
doi = {10.1002/cnr2.1901}
}
EUVIMED